Clinical Trial Update: A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update of CPX-351 (Vyxeos) combined with quizartinib for FLT3-ITD positive acute myeloid leukemia (AML) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)
• Quizartinib (Quizartinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: TERMINATED | Results posted: 2022-06-03